By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Probiodrug AG 

Weinbergweg 22

Halle (Saale)    D-06120  Germany
Phone: 49-345-5559900 Fax: 49-345-5559901


Company News
Key Patents Granted For Probiodrug AG’s pGlu-Abeta Targeting Monoclonal Antibody Program For The Treatment Of Alzheimer’s Disease 1/11/2016 9:55:19 AM
Probiodrug AG Announces Publication Of Initial PQ912 Clinical Data Demonstrating Inhibition Of Glutaminyl Cyclase 12/15/2015 10:47:25 AM
Probiodrug AG Reports Third Quarter 2015 Business Update 11/19/2015 10:32:09 AM
Probiodrug AG Completes Capital Increase 11/6/2015 9:02:50 AM
Probiodrug AG Presented Data On Its pglu-3 Abeta Monoclonal Antibody At Neuroscience 2015, Chicago 10/19/2015 11:21:12 AM
Probiodrug AG Signs Agreement With Rentschler Biotechnologie GmbH & Co. For Manufacture Of Its pGlu-Abeta Targeting Antibody PBD-C06 10/7/2015 11:04:54 AM
Probiodrug AG Licenses The TBA 2.1 Transgenic Alzheimer’s Disease Mouse Model To QPS Austria Neuropharmacology 9/1/2015 9:50:23 AM
Probiodrug AG Funds Brigham and Women's Hospital Research Into Pyroglutamate-Abeta For The Treatment Of Alzheimer’s Disease 7/13/2015 8:37:10 AM
Probiodrug AG Reports First Quarter 2015 Business Update 5/13/2015 12:00:53 PM
Probiodrug AG Release: Key Patents On Glutaminyl Cyclase (QC) Inhibition For The Treatment Of Alzheimer’s Disease Granted In Japan 4/23/2015 9:11:39 AM